VANCOUVER, BC — ME Therapeutics Holdings Inc. (“ME Therapeutics”) a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce its… Read More
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson’s disease spectrum Positive results across all three Phase 3 TEMPO trials reinforce the… Read More
– Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim analysis… Read More
New affinity chromatography resins offer process economy in the capture step In clinical scenario, new resins can reduce consumable cost per gram of mAb by over 30% compared to legacy… Read More
VICTORIA, British Columbia – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with… Read More
